Re: 'Drug-induced Graves disease from CTLA-4 receptor suppression'.

摘要

We read with great interest the case report by Dr. Borodic et al. describing a 51-year-old woman who developed drug-induced Graves disease after undergoing treatment with ipilimumab for metastatic malignant melanoma. Ipilimumab, an IgG1kappa monoclonal antibody inhibiting cytotoxic T-lymphocyte antigen 4, was approved in 2011 as an immunological therapy that extends patient survival in metastatic cutaneous melanoma and may stabilize the disease in patients with metastatic uveal melanoma. However, its antitumor activity is thought to lead to systemic and ocular autoimmune toxicities. We report the first known case of ipilimumab-associated orbitopathy in a patient with metastatic uveal melanoma.